Disclaimer: This is a user generated content submitted by a member of the WriteUpCafe Community. The views and writings here reflect that of the author and not of WriteUpCafe. If you have any complaints regarding this post kindly report it to us.
Roots Analysis has done a detailed study on Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics.”
covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
To order this 400+ page report, which features 145+ figures and 205+ tables, please visit this – https://www.rootsanalysis.com/reports/view_document/blood-brain-barrier-drug-delivery/310.html
Key Market Insights
- More than 110 drugs, capable of penetrating this elusive barrier are currently being evaluated for the treatment of CNS disorders; there are 35+ technology platforms for the development of BBB penetrant drugs
- Majority of drug candidates are currently in the early stages of development, and are intended for the treatment of neurological conditions; a large proportion of the existing pipeline molecules are biologics
- In order to achieve a competitive edge, several technology developers are presently focusing on the integration of advanced technical features into their proprietary drug development / delivery platforms
- An assessment of 240+ drug developers, focused on Parkinson’s and Alzheimer’s diseases, revealed that many such firms are likely to partner with technology providers in order to leverage their BBB penetration expertise
- Over the years, more than 16,700 patents related to BBB technologies have been filed / granted to various industry and non-industry players, indicating the pace of R&D activity in this burgeoning field of research
- Foreseeing a lucrative future, several private and public investors have invested close to USD 1 billion, across more than 70 funding instances
- Revenues generated from the sales of BBB penetrating drugs are anticipated to be well distributed across different types of molecules, target disease indications and various global regions over time
- In the near-term, the opportunity is likely to be driven by licensing activity driven by the capability of leading BBB penetrating technologies to successfully facilitate drug delivery into the brain
For more information, please visit https://www.rootsanalysis.com/reports/view_document/blood-brain-barrier-drug-delivery/310.html
